Mexican consensus on osteoporosis

Revista de Investigacion Clinica

Volumn 53, Issue 5, 2001, Pages 469-495

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTICONVULSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CORTICOSTEROID; CYCLOSPORIN; ESTROGEN DERIVATIVE; GESTAGEN; HEPARIN; IBANDRONIC ACID; PAMIDRONIC ACID; PROGESTERONE DERIVATIVE; PROTIRELIN; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D; BIOLOGICAL MARKER; HORMONE; PHOSPHORUS;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; CHILD; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DRUG POTENTIATION; EPIDEMIOLOGY; FEMALE; HUMAN; MALE; MEDICAL DECISION MAKING; MEXICO; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; PREVALENCE; RADIODIAGNOSIS; BLOOD; BONE; BONE REMODELING; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DRUG CONTRAINDICATION; ECHOGRAPHY; FOLLOW UP; FORECASTING; FRACTURE; MASS SCREENING; METHODOLOGY; MIDDLE AGED; PHOTON ABSORPTIOMETRY; POSTMENOPAUSE OSTEOPOROSIS; RADIOGRAPHY; RISK FACTOR; UNITED STATES;

ABSORPTIOMETRY, PHOTON; AGED; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE REMODELING; CALCITONIN; CALCIUM; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; FORECASTING; FRACTURES, BONE; HORMONES; HUMANS; MALE; MASS SCREENING; MEXICO; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PHOSPHORUS; PREVALENCE; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES; VITAMIN D;

EID: 0035210061     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (179)

1. Consensus Development Conference: Diagnosis, prophylaxis and treatment of osteoporosis
2. The burden of osteoporosis: Costs
3. The economic and human cost of osteoporotic fractures
4. Population-based study of survival after osteoporotic fracture
5. Mortality following hip fracture
6. Survival and ambulation following hip fracture
7. Long-term social prognosis after hip fractures
8. Predictors of functional recovery one year following hospital discharge for hip fracture: A prospective study
9. Quality of life issues in women with vertebral fractures due to osteoporosis
10. Association of osteoporotic vertebral compression fractures with impaired functional status
11. Contribution of vertebral deformities to chronic back pain and disability
12. Colles' fracture: Failure in management may cause permanent disability
13. Decreased incidence of hip fracture in hispanics, Asians and blacks: California hospital discharge data
14. Body size accounts for most differences in bone density between asian and caucasian women
15. A comparison of bone mineral density between caucasian, asian and afro-caribbean women
16. Ethnic differences in hip fracture: A reduced incidence in mexican americans
17. Low risk of vertebral fracture in mexican american women
18. Bone mineral density and mass in a cross-sectional study of white and asian women
19. Sources of interracial variation in bone mineral density
20. Racial differences in femoral dimensions and their relation to hip fracture
21. Bone density and body composition on the Pacific rim: A comparison between japan-born and US-born japanese-american women
22. Hip fractures in the elderly: A worldwide projection
23. Epidemiology of osteoporosis and osteoporotic fractures
24. A model of lifetime osteoporosis impact
25. Osteoporotic fractures: A major health problem in the 1990's
26. Epidemiology of osteoporosis in South America
27. Factores de riesgo en la osteoporosis: Evidencias clínicas y epidemiológicas
28. Epidemiología de fracturas en mayores de 50 años
29. Fracturas de cadera en egresos de hospitales de León, Gto. (México). Un indicador econométrico de osteoporosis
30. Transición demográfica en México, situación de la población anciana
31. How many women have osteoporosis?
32. Prevalence of low femoral bone density in older U.S. women from NHANES III
33. Prevalence of low femoral bone density in older U.S. adults from NHANES III
34. The prevalence of osteoporosis and osteopenia by DEXA in an apparently healthy mexican population. A multicenter study
35. Geographic differences in bone mineral density of mexican women
36. How many women have osteoporosis in Medica. Sur Osteoporosis Clinic
37. Determinants of bone density in normal women: Risk factors for future osteoporosis?
38. Risk factors for osteoporosis
39. Determinants of bone density in normal women: Risk factors for future osteoporosis?
40. Potential risk factors for development of postmenopausal osteoporosis examined over a 12-year period
41. Pre-existing fractures and bone mass predict vertebral fracture incidence in women
42. Factors associated with appendicular bone mass in older women
43. Type of fall and risk of hip and wrist fractures: The Study of Osteoporotic Fractures
44. Bone density at various sites for prediction of hip fractures
45. Long-term fracture prediction by bone mineral assessed at different skeletal sites
46. Factores de riesgo para el desarrollo de osteopenia y su relación con fracturas de cadera
47. Exercise and reproductive factors as predictors of bone density among osteoporotic women in México City
48. Risk factors for hip fracture in white women
49. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures
50. Fall-related factors and risk of hip fracture: The EPIDOS prospective study
51. Risk factors for osteoporotic hip fractures in mexicans
52. Vertebral fractures predict subsequent fractures
53. Forearm fractures as predictors of subsequent osteoporotic fractures
54. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures
55. Nontraumatic lumbar vertebral compression fracture as a risk factor for femoral neck fractures in involutional osteoporotic patients
56. Patients with prior fractures has an increased risk of future fractures: A summary of the literature and statistical synthesis
57. Causes of secondary osteoporosis
58. Calcium intake and bone mass: A quantitative review of the evidence
59. Calcium supplementation and bone loss: A review of controlled clinical trials
60. Therapy of osteoporosis: Calcium, vitamin D, and exercise
61. Is caffeine a risk factor for osteoporosis?
62. Caffeine and other predictors of bone density among pre- and perimenopausal women
63. Associations of parity, breastfeeding and birth control pills with lumbar spine and femoral neck bone densities
64. Pregnancy and lactation as determinants of bone mineral density in postmenopausal women
65. Prediction of perimenopausal fractures by bone mineral density and other risk factors
66. The role of clinical risk factors in the prediction of future fracture risk
67. How should the risk of fracture in postmenopausal women be assessed?
68. Osteoporosis: Assessing and using risk factors for fracture
69. A fracture risk profile using single-site bone density assessment and clinical risk factors
70. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis and therapy
71. The Canadian Consensus Conference on Menopause and Osteoporosis
72. y cols AACE Clinical Practice Guideline for the prevention and treatment of postmenopausal osteoporosis. osteoporosis task force
73. Comité de Expertos de la SIBOMM. Aspectos diagnósticos y terapéuticos de la osteoporosis. Caracas. Junio, 1998
74. Screening for osteoporosis using easily obtainable biometrical data: Diagnostic accuracy of measured, self-reported and recalled BMI, and related costs of bone mineral density measurements
75. Mortality associated with vertebral deformity in men and women: Results from the European Prospective Osteoporosis Study (EPOS)
76. Vertebral fractures and mortality in older women: A prospective study. Study of Osteoporotic Fractures Research Group
77. Risk of mortality following clinical fractures
78. Excess mortality following vertebral fractures
79. A new approach to defining vertebral dimensions
80. Morfometría vertebral radiológica: Valores de índices, alturas y áreas vertebrales en columnas dorsal y lumbar de mujeres mexicanas. Estudio multicéntrico
81. Comparison of methods for in vivo spinal bone measurement
82. Interim Report and Recommendations of the World Health Organization Task Force for Osteoporosis
83. Bone measurements with DXA and ultrasound: Diagnostic and prognostic use
84. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures
85. Clinical assessment of bone mass, quality and architecture
86. National Osteoporosis Foundation. Osteoporosis: Review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. executive summary
87. An update on the diagnosis and assessment of osteoporosis with densitometry
88. Quantitative ultrasound techniques for the assessment of osteoporosis: Expert agreement on current status
89. Broadband ultrasound attenuation predicts fractures strongly and independently of densitometry in older women: A prospective study
90. Noninvasive assessment of bone density and structure using computed tomography and magnetic resonance
91. Marcadores bioquímicos de remodelado óseo para la evaluación de las enfermedades metabólicas óseas
92. Clinical utility of biochemical markers
93. Clinical use of biochemical markers of bone remodeling: Current status and future directions
94. Monitoring osteoporosis therapy with the densitometry misleading changes and regression to the mean
95. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older
96. Evidence that increased calcium intake does not prevent early postmenopausal bone loss
97. Correcting calcium nutritional deficiency prevents spine fractures in elderly women
98. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women
99. Calcium, vitamin D and vitamin K in the prevention of fractures due to osteoporosis
100. Consumo de calcio en mujeres de nivel socioeconómico bajo en León, Gto
101. Calcium, Bone-Active isoflavones and vitamin D metabolites
102. Calcitriol. A review of its use in the treatment of postmenopausal osteoporosis and its potential in corticosteroid-induced osteoporosis
103. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol
104. Treatment of postmenopausal osteoporosis with calcitriol or calcium
105. Rationale for treatment of involutional osteoporosis in women and for prevention and treatment of corticosteroid-induced osteoporosis with alfacalcidol
106. Transplantation osteoporosis and corticosteroid-induced osteoporosis in autoimmune diseases: Experience with alfacalcidol
107. Alphacalcidol in prevention of glucocorticoid-induced osteoporosis. Review
108. Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium
109. Treatment with active vitamin D metabolites and concurrent treatments in the prevention of hip fractures: A retrospective study
110. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and postmenopausal osteoporosis
111. Vitamin D therapy of osteoporosis: Plain vitamin D therapy versus active vitamin D analog (D-hormone) therapy
112. The role of vitamin D in the pathogenesis and treatment of osteoporosis
113. Osteoporosis as a candidate for disease management
114. Cost-Effective treatment strategies for osteoporosis
115. Cost-Effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in post-menopausal women with osteoporosis
116. An assessment of hormone replacement therapy to prevent postmenopausal osteoporosis
117. Hip fracture and the use of estrogens in postmenopausal women: The Framingham Study
118. Estrogen replacement therapy and mortality among older women: The study of osteoporotic fractures
119. Use of estrogen plus progestin is associated with greater increase in breast cancer risk than estrogen alone
120. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk
121. Postmenopausal estrogens-opposed, unopposed, or none of the above
122. Effect of tibolone on postmenopausal bone loss
123. Prevention of post-oophorectomy bone loss with tibolone
124. Tibolone: Prevention of bone loss in late postmenopausal women
125. A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures
126. Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures
127. Treatment of postmenopausal women with osteoporosis for low bone density with raloxifene
128. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene
129. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial: Multiple outcomes of raloxifene evaluation
130. Effect of calcitonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose-response study
131. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study
132. What PROOF proves about calcitonin and clinical trials?
133. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures
134. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women
135. Evidence-Based medicine and osteoporosis: A comparison of fracture risk reduction data from osteoporosis randomised clinical trials
136. Evidence-Based management of patients with osteoporosis
137. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate comparison with either placebo or intranasal salmon calcitonin
138. Bisphosphonates: Pharmacology, mechanisms of action and clinical uses
139. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis
140. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
141. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study
142. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis
143. Alendronate and estrogen-progestin in the long-term prevention of bone loss: Four years results
144. Association of prevalent vertebral fractures, bone density, and alendronate treatment with incidental vertebral fractures: Effect of number and spinal location of fractures
145. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial
146. Skeletal benefits of alendronate: 7 years treatment of postmenopausal osteoporotic women
147. Alendronate in the treatment of osteoporosis: A review of the clinical trials
148. Effect of alendronate on limited-activity days and bed disability days cause by back pain in postmenopausal women with existing vertebral fractures
149. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures
150. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis
151. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trial
152. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: A prospective multicenter study
153. Alendronate for the treatment of osteoporosis in men
154. Effects of alendronate on bone density in men with primary and secondary osteoporosis
155. Weekly administration of alendronate: Rational and plan for clinical assessment
156. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis
157. Effects of risendronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis
158. Randomized trial of the effects of risendronate on vertebral fractures in women with established postmenopausal osteoporosis
159. Effect of risendronate on the risk of hip fracture in elderly women
160. Risendronate Therapy prevents corticosteroid-induced bone loss
161. Prevention of bone loss with risendronate in glucocorticoid-treated rheumatoid arthritis patients
162. Efficacy and safety of daily risendronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study
163. Effects of risendronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy
164. An endoscopic comparison of the effects of Alendronate and risendronate on upper gastrointestinal mucosae
165. Treatment of osteoporosis: Role of bone forming agents
166. Anabolic therapy for osteoporosis
167. The Parathyroid Hormones: Bone-forming agents for treatment of osteoporosis
168. Stimulation of bone formation in vitro and in rodents by statins
169. Do statins prevent both cardiovascular disease and fracture?
170. Effect of pravastatin on frequency of fracture in the LIPID study: Secondary analysis of a randomized controlled trial. Long-term intervention with pravastatin in ischemic disease
171. Four-year randomized prospective study: An efficacious therapy for established post-menopausal osteoporosis with the combination of estrogen and biphosphonate
172. Additon of Alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis. A randomized controlled clinical trial
173. Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: A prospective randomized study
174. Alendronate and estrogen effects in postmenopausal women with low bone mineral density
175. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women
176. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate
177. Prevention and treatment of osteoporosis: Efficacy of combination of hormone replacement therapy with other antiresorptive agents. Review article
178. Prevention of hip fracture in elderly people with use of a hip protector